

Clinical trials of antiplatelets drug for acute coronary syndrome in patients with scheduled percutaneous coronary intervention

TrialResults-center www.trialresultscenter.org

1 platelet aggregation inhibitors

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|---------------------------|
| ASA high dose vs ASA low dose | | | |
| CURRENT - OASIS 7 (ASA) , 2010 [NCT00335452] n=12507/12579 follow-up: 30 days | High-dose aspirin versus Low-dose aspirin | ACS patients referred for an invasive strategy (scheduled for percutaneous coronary intervention no more than 72 hours after randomization) | Factorial plan open |

References

CURRENT - OASIS 7 (ASA), 2010:

Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Fox KA, Granger CB, Jolly S, Rupprecht HJ, Widimsky P, Yusuf S Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J 2008 Dec;156:1080-1088.e1 [[19033002](#)]

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010 Sep 2;363:930-42 [[20818903](#)] [10.1056/NEJMoa0909475](#)

2 thienopyridine

| Trial | Treatments | Patients | Trials design and methods |
|---|--|---|---|
| prasugrel vs clopidogrel | | | |
| TRITON-TIMI 38 , 2007 [NCT00097591] n=6813/6795 follow-up: | prasugrel 60-mg loading dose and 10-mg daily maintenance dose, for 6 to 15 months versus clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose) for 6 to 15 months | patients with moderate-to-high-risk acute coronary syndromes (UA, NSTEMI,STEMI) with scheduled percutaneous coronary intervention | Parallel groups double blind 30 countries |
| clopidogrel high-dose regimen vs clopidogrel standard-dose | | | |
| CURRENT OASIS 7 (clopidogrel) , 2010 [NCT00335452] n=12520/12566 follow-up: 30 days | Double-dose clopidogrel versus Standard-dose clopidogrel | ACS patients referred for an invasive strategy (scheduled for percutaneous coronary intervention no more than 72 hours after randomization) | Factorial plan open |

References

TRITON-TIMI 38, 2007:

Antman EM, Wiviott SD, Murphy SA, Voitek J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe CH, Braunwald E Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. *J Am Coll Cardiol* 2008 May 27;51:2028-33 [[18498956](#)]

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2007;357:2001-15 [[17982182](#)]

CURRENT OASIS 7 (clopidogrel), 2010:

Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Fox KA, Granger CB, Jolly S, Rupprecht HJ, Widimsky P, Yusuf S Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. *Am Heart J* 2008 Dec;156:1080-1088.e1 [[19033002](#)]

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. *N Engl J Med* 2010 Sep 2;363:930-42 [[20818903](#)] [10.1056/NEJMoa0909475](#)

Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. *Lancet* 2010 Sep 1; [[20817281](#)] [10.1016/S0140-6736\(10\)61088-4](#)

3 About TrialResults-center.org

↳ TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.